125 related articles for article (PubMed ID: 38011024)
1. Impact of Pretreatment Weight Loss on Radiotherapy Utilization and Clinical Outcomes in Non-Small Cell Lung Cancer.
Alvarez CM; Aliru M; Gannavarapu BS; Song T; Gilmore LA; Olaechea S; Gomez DR; Ahn C; Infante RE; Iyengar P
Am J Clin Oncol; 2024 Feb; 47(2):49-55. PubMed ID: 38011024
[TBL] [Abstract][Full Text] [Related]
2. Comparison of outcomes in patients with stage III versus limited stage IV non-small cell lung cancer.
Cheruvu P; Metcalfe SK; Metcalfe J; Chen Y; Okunieff P; Milano MT
Radiat Oncol; 2011 Jun; 6():80. PubMed ID: 21718501
[TBL] [Abstract][Full Text] [Related]
3. Impact of Socioeconomic Status on Pretreatment Weight Loss and Survival in Non-Small-Cell Lung Cancer.
Lau SKM; Gannavarapu BS; Carter K; Gao A; Ahn C; Meyer JJ; Sher DJ; Jatoi A; Infante R; Iyengar P
J Oncol Pract; 2018 Apr; 14(4):e211-e220. PubMed ID: 29558251
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
5. Population-based analysis of curative therapies in stage II non-small cell lung cancer: the role of radiotherapy in medically inoperable patients.
Moore S; Leung B; Wu J; Ho C
Radiat Oncol; 2020 Jan; 15(1):23. PubMed ID: 32000829
[TBL] [Abstract][Full Text] [Related]
6. Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer.
Voong KR; Hazell SZ; Fu W; Hu C; Lin CT; Ding K; Suresh K; Hayman J; Hales RK; Alfaifi S; Marrone KA; Levy B; Hann CL; Ettinger DS; Feliciano JL; Peterson V; Kelly RJ; Brahmer JR; Forde PM; Naidoo J
Clin Lung Cancer; 2019 Jul; 20(4):e470-e479. PubMed ID: 31031204
[TBL] [Abstract][Full Text] [Related]
7. Treatment with curative intent of stage III non-small cell lung cancer patients of 75 years: a prospective population-based study.
Wanders R; Steevens J; Botterweck A; Dingemans AM; Reymen B; Baardwijk Av; Borger J; Bootsma G; Pitz C; Lunde R; Geraedts W; Lambin P; De Ruysscher D
Eur J Cancer; 2011 Dec; 47(18):2691-7. PubMed ID: 21733675
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes and radiation pneumonitis after concurrent EGFR-tyrosine kinase inhibitors and radiotherapy for unresectable stage III non-small cell lung cancer.
Xu K; Liang J; Zhang T; Zhou Z; Chen D; Feng Q; Xiao Z; Hui Z; Lu J; Wang X; Deng L; Liu W; Wang J; Zhai Y; Wang J; Bi N; Wang L
Thorac Cancer; 2021 Mar; 12(6):814-823. PubMed ID: 33501781
[TBL] [Abstract][Full Text] [Related]
9. 30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study.
Wallington M; Saxon EB; Bomb M; Smittenaar R; Wickenden M; McPhail S; Rashbass J; Chao D; Dewar J; Talbot D; Peake M; Perren T; Wilson C; Dodwell D
Lancet Oncol; 2016 Sep; 17(9):1203-16. PubMed ID: 27599138
[TBL] [Abstract][Full Text] [Related]
10. The impact of PET and PET/CT on treatment planning and prognosis of patients with NSCLC treated with radiation therapy.
Nawara C; Rendl G; Wurstbauer K; Lackner B; Rettenbacher L; Datz L; Studnicka M; Sedlmayer F; Pirich C
Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):191-201. PubMed ID: 22402822
[TBL] [Abstract][Full Text] [Related]
11. Individualised isotoxic accelerated radiotherapy and chemotherapy are associated with improved long-term survival of patients with stage III NSCLC: a prospective population-based study.
De Ruysscher D; van Baardwijk A; Steevens J; Botterweck A; Bosmans G; Reymen B; Wanders R; Borger J; Dingemans AM; Bootsma G; Pitz C; Lunde R; Geraedts W; Oellers M; Dekker A; Lambin P
Radiother Oncol; 2012 Feb; 102(2):228-33. PubMed ID: 22100659
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Yuan Y; Wan X; Yin D; Li R; Chen W; Suo C; Song H
Cochrane Database Syst Rev; 2021 Dec; 12(12):CD011300. PubMed ID: 34870327
[TBL] [Abstract][Full Text] [Related]
13. Prognostic effect of cachexia in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
Matsuo N; Azuma K; Murotani K; Murata D; Matama G; Kawahara A; Kojima T; Tokito T; Hoshino T
Thorac Cancer; 2023 May; 14(15):1362-1367. PubMed ID: 37037511
[TBL] [Abstract][Full Text] [Related]
14. The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R): Real-World Data on Stage III Non-Small Cell Lung Cancer Patients Treated With Curative Chemoradiation.
Dieleman E; van der Woude L; van Os R; van Bockel L; Coremans I; van Es C; De Jaeger K; Knol HP; Kolff W; Koppe F; Pomp J; Reymen B; Schinagl D; Spoelstra F; Tissing-Tan C; van der Voort van Zyp N; van der Wel A; Wijsman R; Dielwart M; Wiegman E; Damhuis R; Belderbos J
Clin Lung Cancer; 2023 Mar; 24(2):130-136. PubMed ID: 36572596
[TBL] [Abstract][Full Text] [Related]
15. A decade of community-based outcomes of patients treated with curative radiotherapy with or without chemotherapy for non-small cell lung cancer.
Pramana A; Descallar J; Vinod SK
Asia Pac J Clin Oncol; 2016 Sep; 12(3):e357-66. PubMed ID: 25155757
[TBL] [Abstract][Full Text] [Related]
16. Radiation therapy of stage I and II non-small cell lung cancer (NSCLC).
Zierhut D; Bettscheider C; Schubert K; van Kampen M; Wannenmacher M
Lung Cancer; 2001 Dec; 34 Suppl 3():S39-43. PubMed ID: 11740992
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab.
Jo H; Yoshida T; Horinouchi H; Yagishita S; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Yamamoto N; Takahashi K; Motoi N; Ohe Y
Cancer Immunol Immunother; 2022 Feb; 71(2):387-398. PubMed ID: 34180007
[TBL] [Abstract][Full Text] [Related]
18. Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients-Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study.
Takayama K; Atagi S; Imamura F; Tanaka H; Minato K; Harada T; Katakami N; Yokoyama T; Yoshimori K; Takiguchi Y; Hataji O; Takeda Y; Aoe K; Kim YH; Yokota S; Tabeta H; Tomii K; Ohashi Y; Eguchi K; Watanabe K
Support Care Cancer; 2016 Aug; 24(8):3473-80. PubMed ID: 27003901
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of a Highly Selective Surgical Approach to Oligometastatic Lung Cancer.
Johnson KK; Rosen JE; Salazar MC; Boffa DJ
Ann Thorac Surg; 2016 Oct; 102(4):1166-71. PubMed ID: 27344278
[TBL] [Abstract][Full Text] [Related]
20. The Role of a Cachexia Grading System in Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy: Implications for Survival.
Turcott JG; Martinez-Samano JE; Cardona AF; Bassarmal SS; Ramírez-Tirado LA; Zatarain-Barrón ZL; Barrón F; Corrales L; Martín C; Barragán-Castillo PA; Ruiz-Patiño A; Flores-Estrada D; Arrieta O
Nutr Cancer; 2021; 73(5):794-801. PubMed ID: 32482104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
